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Abstract
First seen as a storage organ, the white adipose tissue (WAT) is now considered as an endocrine organ. WAT can
produce an array of bioactive factors known as adipokines acting at physiological level and playing a vital role in
energy metabolism as well as in immune response. The global effect of adipokines in metabolic activities is well
established, but their impact on the physiology and the pathophysiology of the central nervous system (CNS)
remains poorly defined. Adipokines are not only produced by the WAT but can also be expressed in the CNS where
receptors for these factors are present. When produced in periphery and to affect the CNS, these factors may either
cross the blood brain barrier (BBB) or modify the BBB physiology by acting on cells forming the BBB. Adipokines
could regulate neuroinflammation and oxidative stress which are two major physiological processes involved in
neurodegeneration and are associated with many chronic neurodegenerative diseases. In this review, we focus on
four important adipokines (leptin, resistin, adiponectin, and TNFα) and one lipokine (lysophosphatidic acid—LPA)
associated with autotaxin, its producing enzyme. Their potential effects on neurodegeneration and brain repair
(neurogenesis) will be discussed. Understanding and regulating these adipokines could be an interesting lead to
novel therapeutic strategy in order to counteract neurodegenerative disorders and/or promote brain repair.
Keywords: Diabetes, Obesity, White adipose tissue, Adipocytokines, Central nervous system, Neuroinflammation,
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Background
Obesity and type 2 diabetes mellitus (T2DM) are main
health issues in our modern societies and constitute very
important public health challenges [1–3]. The World
Health Organization (WHO) reported that worldwide
obesity has more than doubled since 1980 and more
than 1.9 billion adults were overweight in 2014 [2]. One
result from excess body weight and physical inactivity is
the dramatic development of type 2 diabetes that WHO
has predicted to be the seventh leading cause of death in
2030 [3–5]. In parallel, 35.6 million people display
dementia and 7.7 million new cases are reported every
year, Alzheimer’s disease (AD) being the main cause of
dementia [6, 7]. An increasing number of data recently
highlights that metabolic syndrome, notably obesity and
type 2 diabetes, are correlated with an increased risk to
develop dementia and/or neurodegenerative diseases
such as AD, as well as neurological and neurovascular
disorders [8–11]. Consequently, adiposity has been
proposed as an independent factor favoring the devel-
opment of AD [12–14]. However, breaking the para-
digm, recent studies show that underweight people
(BMI < 20 kg/m2) display higher risk of dementia
while very obese people (BMI > 40 kg/m2) have lower
dementia risk than healthy weight people [15]. Simi-
larly, a decrease in BMI from mid-life to late-life has
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been correlated with an increased risk of dementia
[16]. Interestingly, it has been suggested that the mis-
expression of adipose-derived factors called adipokines
or adipocytokines may disrupt directly or indirectly
brain homeostasis and functions.
In this review, we aimed at first describing the links
between adiposity, adipokines levels, and neurological dis-
orders. Furthermore, adipokine signaling in the central
nervous system (CNS), highlighting their potential effects
on cognition, neurogenesis, and brain functioning, has
also been explored. Finally, the possibilities of adipokines
to disturb brain physiology and functions through blood
brain barrier disruption resulting from increased inflam-
mation and oxidative stress have been discussed.
White adipose tissue: not just energy storage
White adipose tissue secretes adipokines
White adipose tissue (WAT) was originally described to
store energy in the form of triglycerides. However, since
the discovery of the leptin hormone in 1994, WAT is
also recognized as a major endocrine organ secreting a
wide variety of biologically active factors collectively
called adipokines or adipocytokines [17, 18]. To date,
about hundred adipokines constituting the adipokinome
have been documented to be released from white adipo-
cytes [19]. The most studied adipokines are leptin,
adiponectin, apelin, resistin, monocytes, and macrophage
chemotactic protein 1 (MCP1), interleukin-1β (IL-1β),
interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necro-
sis factor-alpha (TNFα), and transforming growth factor
(TGFβ). In addition to adipokines, lipid-derived factors
(sometimes referred as lipokines) such as the lysopho-
sphatidic acid are also important mediators produced by
the fat tissue [20, 21]. Pro-inflammatory factors include
adipokines such as leptin, TNFα, and IL-6, while anti-
inflammatory ones include adiponectin and the secreted
frizzled-related protein 5 (sFRP5) [20, 22, 23]. Adipo-
kines exert pleiotropic effects on different tissues such
as the lung, skeletal muscle, heart, liver, and blood ves-
sels and regulate numerous physiological functions such
as appetite, energy expenditure, insulin sensitivity and
secretion, fat distribution, lipid and glucose metabolism,
endothelial function, blood pressure, hemostasis, neuro-
endocrine functions, and also immunity [18, 21, 24–28].
The data generated over the last 20 years considerably
change our view on adipose tissue as WAT plays a wide-
ranging role in metabolic regulation and physiological
homeostasis [17, 18].
Adipokines and diseases: focus on neurological disorders
and diseases
The dysregulation of adipokine production and/or levels
has been correlated with several diseases and could not-
ably promote and/or result in obesity-linked metabolic
disorders [27, 29]. Thus, low plasmatic leptin concentra-
tions are associated with an increased risk for cardiovascu-
lar diseases [30]. In contrast, higher plasmatic adiponectin
levels seem to be associated with decreased risk for devel-
oping type 2 diabetes mellitus (T2DM) [31]. Other data
also show relationships between MCP-1 serum levels and
insulin resistance, as diabetic patients exhibit highest
MCP-1 levels [32]. In the same line of evidences, it
appears that the inflammatory status of WAT in obese
patients might be a key player linking high WAT mass to
insulin resistance. Interestingly, an increasing number of
studies reported links between metabolic disorders (i.e.,
T2DM and obesity) and brain homeostasis and function-
ing [9, 12, 33–39]. Initial studies demonstrated that a
higher body mass index (BMI) and/or waist-to-hip ratio in
middle-aged individuals is associated with a reduction in
the whole brain volume. Indeed, over the last decade, a
number of magnetic resonance imaging (MRI) and
computed tomography (CT) studies also reported alter-
ations in brain morphology of overweight/obese individuals
[40–42]. Studies documented a link between abdominal fat
and reduced brain volume in healthy middle-aged adults
notably the temporal lobe volume and the hippocampus
[43, 44]. In a cross-sectional study of normal elderly indi-
viduals showing no sign of cognitive deficit, tensor-based
morphometry also unveiled atrophy in the white and gray
matter of the frontal lobes, anterior cingulate gyrus, hippo-
campus, and thalamus in both male and female subjects
with a high BMI (BMI > 30) as compared to individuals
with a normal BMI (18.5–25) [45]. Upon further investiga-
tion, the brain volume reduction in gray and white matter
was found to be associated with a common variant of
the fat mass and obesity-associated (FTO) gene [46].
In addition, a growing body of studies also show that
obesity in mid-life is a predictor of mild cognitive im-
pairment with aging and altered executive function
and short-term memory compared to normal weight
counterparts [39, 47–49]. Such data were also con-
firmed in rodents for which high fat diets result in
impaired cognitive functions including a decrease in
memory performance, learning, and executive func-
tions [39, 50, 51]. Furthermore, during the develop-
ment of obesity in rodent models, it appears that
neurochemical changes occurs in the brain altering
cognition processes, reward neurocircuitry, and stress
responsiveness [52]. Consequently, numerous studies
described association between rich diets (sugar and/or fat)
and cognitive defects in rodents and humans [39, 52], and
it seems that such effects of diets could occur through the
disruption of neurovascular function [52–54]. In addition,
a linkage has been demonstrated between overweight,
neuroinflammation, and neurodegenerative diseases namely
AD, Parkinson’s disease (PD), and autoimmune nervous
system diseases such as multiple sclerosis [9, 12, 33–38].
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Similarly, T2DM is associated to impaired cognition, espe-
cially learning and memory deficits such as shown in
rodents and humans while such effects are rarely observed
in type 1 diabetes [55, 56]. This is peculiarly interesting
given that T2DM patients are mostly overweight or obese
compared to type 1 diabetic. In a recent study, working on
80 T2DM patients and 80 healthy controls demonstrated a
cortical and subcortical atrophy and that cognition impair-
ment was correlated with reduced hippocampal CA1 size
in the diabetic group [57]. Diabetes is associated with an
increased risk of AD and vascular dementia, supported by
increasing oxidative stress and inflammation and impaired
insulin and amyloid metabolisms [56, 58–62]. T2DM pa-
tients also display lower cerebral blood flow and neural
slowing on recordings of sensory-evoked potentials [56].
Numerous studies performed on rodents also show an
impact of diabetes on neurogenesis, depression, and
cognition [63].
Taken together, these data show that obesity and
diabetes have negative effects on brain structures and/or
functions. It also raises the question about the roles of
adipokines in such neurological disorders. A possible
explanation could be that abnormal adipokine concen-
trations, such as increase pro-inflammatory adipokines
TNFα, resistin, leptin, IL-1β, and also IL-6, could influ-
ence the blood brain barrier integrity and disrupt brain
homeostasis through oxidative stress and inflammation
[12, 20]. In the following part, we aim to describe the
effects of some adipokines in the brain, regarding their
transport in the central nervous system and their signaling.
Adipokines and targets in the brain
In this part, we focus on specific adipokines (leptin,
resistin, adiponectin, TNFα) and also on a lipokine of
interest, the lysophosphatidic acid (LPA) and their
targets in the brain as well as their potential impact on
brain inflammation and functions (Fig. 1).
Leptin
Leptin is probably the most studied adipose-derived
hormones. Leptin which is mainly produced by adipo-
cytes exerts its effects both peripherally and centrally
[17, 21, 24, 64]. This adipokine plays a key role in
regulating energy intake and expenditure, metabolism,
and behavior by directly acting on the CNS. Mice
invalidated for leptin (ob/ob mice) display obesity, insulin
resistance, and hyperphagia showing notably the impact of
this adipose-derived hormone on feeding behavior [65].
Peripheral leptin exerts its central effect through its bind-
ing at the level of choroid plexus leading to its transport
across the blood brain barrier [66–69]. Such a transport
involved leptin receptors and probably other mechanisms
that are still poorly understood [9]. However, some studies
have shown that leptin could be also locally and de novo
produced in the brain, in the cerebellum, the cortex, and
the hypothalamus [70–73], suggesting other specific and
Fig. 1 Effects of the main adipokines on brain homeostasis/functions. LPA lisophosphatidic acid, TNFα tumor necrosis factor-α
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local functions for leptin than those previously described.
Leptin receptors belong to the family of cytokine recep-
tors, and at least five different isoforms have been identi-
fied in mouse: Ob-Ra to Ob-Re [65, 74]. In the CNS,
leptin receptors (Ob-R or LepR) were first identified in
choroid plexus and in the hypothalamus [75, 76]. Among
all Ob-R isoforms, only the full-length isoform (Ob-Rb)
appears to fully transduce the activation signal at least in
the brain and is essential for leptin’s weight-reducing
effects [65, 74]. Ob-Rb is expressed in the hypothalamic
nuclei notably in the arcuate nucleus (ARC), the dorsome-
dial nucleus (DMH), the paraventricular nucleus (PVN),
the ventromedial hypothalamic nucleus (VMH), and the
lateral hypothalamic nucleus (LH) [65, 77, 78] but is also
detected in the neocortex, the hippocampus, the hind-
brain (nucleus of the solitary tract), the ventral tegmental
area, the medulla, and the cerebellum [77, 79–83]. In
addition, a weaker expression was also detected by in situ
hybridization in the hippocampus and the thalamus [77].
The expression of leptin receptors and leptin mRNAs is
documented in the mouse brain and notably in the main
neurogenic niches, the subventricular zone of the lateral
ventricles, and the dentate gyrus of the hippocampus
(Allen Brain Atlas [http://www.brain-map.org], [84]). This
work clearly illustrates the expression of leptin receptors
in the cortex, along the ventricular walls and also in the
hippocampus. Leptin is expressed in the same regions at
lower levels. In the hypothalamus, the primary leptin
targets are the orexigenic agouti-related peptide (AgRP)
neurons and the anorexigenic pro-opiomelanocortin
(POMC) neurons that are involved in feeding behavior.
Thus, in the CNS, leptin activates anorexigenic POMC
neurons through a neural network in the arcuate nucleus
[85]. The appetite-stimulating effects of AgRP/NPY are
inhibited by leptin in the arcuate nucleus avoiding the
release of orexigenic factors [86, 87]. Furthermore, leptin
receptors were also expressed in glutamatergic and
GABAergic neurons [78, 88, 89]. Vong and colleagues
(2011) have shown that the main effects of leptin are
mediated by GABAergic neurons and only barely by gluta-
matergic neurons [88]. However, it was recently demon-
strated that glutamate release mediates leptin action on
energy expenditure [89]. We realize now that the effects
of leptin on these different neuronal types and brain
nuclei are not so easy to understand as originally thought.
In homeostatic conditions, leptin inhibits food intake, and
in extra-hypothalamic sites, leptin acts on neurogenesis,
synaptogenesis, neuronal excitability, and neuroprotection
[9, 90, 91]. Leptin was also shown to improve cognition
and mood in depressed and anxious animal models,
notably by improving long-term potentiation [9]. Leptin
levels negatively correlated with the development of
Alzheimer’s disease in lean humans [91, 92], and leptin
signaling seems to be dysregulated in Alzheimer’s disease
brains [93]. Interestingly, there are also positive correlations
between plasma levels of leptin and body weight [94, 95].
Resistin
Resistin (or adipose tissue-specific secretory factor:
ADSF or C/EBP-epsilon-regulated myeloid-specific se-
creted cysteine-rich protein: XCP1) is a cysteine-rich
adipose-derived peptide hormone, encoded by the RETN
gene, and known for its implication in inflammatory
processes [20, 96]. Its expression increases in parallel to
adiposity [97–99] and is strongly related to insulin resist-
ance in obese rodents [100]. Interestingly, in humans,
resistin is mainly expressed and secreted by macro-
phages while adipocytes are the main source in rodents
[100]. Resistin is known to play a key role in the CNS
notably by regulating pituitary somatotrope cell func-
tions [101], affecting hypothalamic and peripheral insu-
lin responsiveness, thermogenesis, and feeding behavior,
and also by enhancing renal sympathetic nerve activity
[102–104]. However, the resistin receptor and the mo-
lecular mechanisms sustaining such effects are poorly
understood and mainly unexplored until recently. Al-
though resistin receptor has not been clearly identified,
some potential candidate receptors have been proposed
in different cell types such as an isoform of decorin (a
small proteoglycan associated with collagen fibrils) in
adipose progenitor cells, tyrosine kinase-like orphan
receptor-1 (ROR1) in 3T3-L1 cells [105] or IGF-1R in
fibroblast [106]. Nevertheless, it has been shown that
resistin administration modulates or activates several
signaling pathway involving Gs protein-dependent
mechanisms, the adenylate cyclase/cAMP/protein kinase
A pathway, the phosphatidylinositol 3-kinase/Akt path-
way, the protein kinase C, and extracellular Ca2+ sig-
naling through L-type voltage-sensitive Ca2+ [102, 107].
Such puzzling data strongly suggest that resistin could
potentially interact with different receptors depending
on tissue and cell types. Furthermore, resistin also regu-
lates the synthesis and secretion of the pro-inflammatory
cytokines TNFα and IL-6 through nuclear factor-κB-
dependent pathway in macrophage [108–110]. Recently,
Toll-like receptor 4 (TLR-4) receptors were identified as
potential receptor for resistin in the hypothalamus,
leading to the activation of JNK and p38/MAPK path-
ways [111]. Interestingly, resistin was also reported to be
expressed in the hypothalamus and the cortex and to
inactivate hypothalamic neurons [112–114]. In the rat
brain, resistin is de novo produced suggesting specific
roles for this local synthesis [114]. Resistin gene expres-
sion in the brain of mouse is reported in the cortex
along the walls of the lateral ventricles and also in the
hippocampus (Allen Brain Atlas [http://www.brain-
map.org], [84]). In rat, traumatic brain injury (TBI)
increased resistin mRNA expression in the ipsilateral
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cortex without any effects on the contralateral hemi-
sphere. However, resistin expression is upregulated after
TBI in the ipsi- and contralateral hippocampus [73].
One explanation is that given TBI compromises the in-
tegrity of the blood brain barrier, it could result in the
changes in gene expression in the contralateral side of
the hippocampus by exposing the brain to circulating
factors of peripheral origin (Brown et al., 2008). The
relatively rapid increase of resistin expression following
TBI (at 12 h post-injury), is in contrast to the delayed
upregulation of resistin in hypoxic ischemic mouse brain
(>7 days) [115]. Thus, resistin could participate in the
acute responses to cerebral damage probably through
inflammatory mechanisms. A recent study suggested
that resistin was not related to cognitive function
performance [116].
Adiponectin
Adiponectin was first characterized in 1995 in 3T3-L1
adipocyte differentiation [117]. It is one of the most
abundant adipokines considering its concentration in
plasma relative to many other hormones [118, 119]. Adi-
ponectin self-associates into larger structures forming
homotrimers that also self-associate and form hexamers
or dodecamers. A globular fraction, named globular adi-
ponectin, resulting from the cleavage of the full-length
monomer, was also documented [120]. Adiponectin is
mainly synthesized and secreted by adipocytes. However,
it is now well admitted that adiponectin is expressed at
the mRNA and/or protein level by the placenta, the liver,
epithelial cells, osteoblasts, myocytes, and also by pituit-
ary cells [114, 119, 121]. Interestingly, some studies
documented adiponectin transcript expression in the
diencephalon of chicken [114, 122] and in the human
pituitary [121]. In the pituitary, adiponectin could have a
role in the release of somatotrophs and gonadotrophs
[119]. It also modulates a wide range of metabolic pro-
cesses such as body-weight regulation, glucose regulation,
insulin sensitivity, lipid catabolism (fatty acid oxidation),
endothelial function, and also anti-atherogenic process
[119, 123–126]. Such effects are mediated by three
different receptor types: adiponectin receptor 1 (Adipo-
R1), adiponectin receptor 2 (Adipo-R2), and T-cadherin
(CDH13) and involved different signaling pathways in-
cluding AMPK, p38-MAPK, JNK, PPAR-α, and NF-kB.
These receptors appear to be widely expressed in the
mammalian brain including mouse, rat, pork and human.
Their expression was documented in different brain struc-
tures such as the pituitary, the hypothalamus, and in
cortical and subcortical neurons [97, 119, 121, 127–131].
In their review, Thundyil and colleagues (2012) docu-
mented adiponectin receptor expression in the central
nervous system showing that Adipo-R1 is mainly expressed
in the hypothalamus, the brainstem, and the pituitary gland
while Adipo-R2 seems to be mostly expressed in the cortex.
Furthermore, Adipo-R1 is strongly expressed in neurons
and to a lesser extent in astrocytes while Adipo-R2 is
figured to be only weakly expressed in astrocytes and neu-
rons [119]. Adiponectin gene expression is widely expressed
in the cortex and the hippocampus. Concerning T-cadherin
receptor, it seems to be temporally and spatially expressed
in different neuronal populations during axon growth
[132]. Furthermore, T-cadherin showed broad expression in
the cerebral cortex, basal ganglia, amygdala, and hippocam-
pus in the developing postnatal telencephalon of marmoset
(Callithrix jacchus) [133]. In mouse, CDH13 was also
expressed by projection neurons within the main and
accessory olfactory bulbs. Interestingly, adiponectin
deficiency is associated with exaggerated inflammatory
response in critical illness or septic patients [134–136].
Recently, Adipo-R1 and Adipo-R2 expression was de-
scribed in both U373 MG (human glioblastoma astrocy-
toma cell line) and primary human astrocytes [137]. It
also appears that adiponectin induces a pro-inflammatory
response in human astrocytes, increasing notably IL-6 and
MCP-1 through NF-κB, p38MAPK, and ERK1/2 pathways
(Wan et al., 2014). In contrast, adiponectin was described
to inhibit pro-inflammatory signal, notably by suppressing
IL-6 release from blood brain barrier (BBB) endothelial
cells [138]. It results that adiponectin indirectly modulates
inflammatory signaling across the BBB by negatively
modulating IL-6 and TNFα release. In vitro experiment of
hippocampal neurons reveals that adiponectin exerts
neuroprotective effects through AMPK pathway [139].
Such neuroprotective effects of adiponectin are further
reinforced by the fact that knock-out mice for adiponectin
exhibit more brain damages after ischemic stroke to
controls [140]. This neuroprotective action is mediated
through an endothelial nitric oxide synthase (eNOS)-
dependent mechanism [140].
Tumor necrosis factor α
Many pro-inflammatory factors are produced in acti-
vated WAT, such as TNFα, IL-1, and PGE2. We choose
to describe in more depth the prototype inflammatory
cytokine TNFα. TNFα is a pro-inflammatory adipokine
well-known for its role in chronic peripheral and central
inflammation [9, 141]. TNFα is primarily produced as a
transmembrane protein that self-associated into stable
homotrimers [142, 143]. Such homotrimers could be
cleaved by the TNFα-converting enzyme (TACE, also
called ADAM17), allowing the release of secreted form
of TNFα [144]. In WAT, TNFα is produced by macro-
phages as well as by adipocytes, and its expression is in-
creased at the mRNA and protein levels in obese and in
T2DM models [145]. TNFα actions are mediated by two
receptors: TNF-R1 (TNF-RSF1a) and TNF-R2 (TNF-
RSF1b). TNF-R1 is expressed in most tissues and can be
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fully activated by both the membrane-bound and soluble
trimeric forms of TNF, while TNF-R2 is found in a
limited cell types including cell of the immune system,
oligodendrocytes, and certain neuron subtypes and
responds to the membrane-bound form of the TNF
homotrimer [9]. TNF-R1 and TNF-R2 are also expressed
in the cortex, the subventricular zone of the lateral
ventricle, and the hippocampus (Allen Brain Atlas
[http://www.brain-map.org], [84]). In homeostatic condi-
tions, the TNFα gene expression is low. However, in
stress conditions (infection, trauma, pathologies), TNFα
level can increase dramatically. As most information
regarding TNF signaling is derived from TNF-R1, the
role of TNF-R2 is likely underestimated. In rodents,
TNFα has been shown to be transported across the BBB,
but to be also locally produced by microglia, astrocytes
and neurons in the brain [146–148]. In the CNS, TNFα
acts through TNF-receptors on neurons and astrocytes
regulating a wide range of cellular processes such as cell
survival [9, 149, 150]. Actually, TNFα exhibits pleio-
tropic effects with positive and negative outcomes on
the brain. On the one hand, TNFα is considered as the
prototypic inflammatory cytokine and elevated levels of
TNF have been described in many neurodegenerative
situations [151, 152]. For instance, we have demon-
strated the role of TNF in chemically induced neurode-
generation [153]. On the other hand, inhibition of TNF
in inflammatory peripheral diseases induced CNS side
effects including demyelination and neuropathies, sug-
gesting a positive role for TNF maintaining the homeo-
stasis in the CNS [154]. It acts on neurogenesis, synaptic
transmission, and plasticity [9]. Thus, TNFα was described
for its neuroprotective roles on hippocampal neurons by
suppressing the accumulation of reactive oxygen species
(ROS) and by maintaining intracellular levels of calcium
[155]. In addition, it modulates glutamatergic transmission
[156]. Furthermore, TNFα favors neural progenitor cell
survival by mediating anti-apoptotic signals via TNF-R2
[157]. In rat, TNFα appears to promote the survival of
stroke-generated hippocampal and striatal neurons [158].
In addition, TNFα knock-out mice show cognitive impair-
ment (i.e., significant poorer learning, retention, and
spatial learning), suggesting a strong role for TNFα on
these mechanisms [159]. However, TNFα also exhibits a
dark face, as reported in numerous other studies. It is
notably involved in myelin damages [160], in favoring
glutamate excitotoxicity [161], in inhibition of long-term
potentiation in Cornu Ammonis area 1 (CA1) and in the
dentate gyrus of the rat hippocampus [150, 162, 163] and
in decreasing neurogenesis [164, 165].
Altogether, these data established that the role of
TNFα is complex. TNFα could exhibit multiple faces
exerting neuroprotective versus neurotoxic roles, pro-
versus anti-neurogenic effects according to the conditions
(concentrations, physiological, or pathological condi-
tions…). Neuroinflammation and metabolic disorders
such as obesity could act on these mechanisms through
an excess of TNFα secretion.
Lysophosphatidic acid
Among the factors secreted by the adipose tissue, there
are many lipids from the lipokine family such as prosta-
glandin E2 (PGE2), anandamide, and also lysophosphati-
dic acid (LPA). LPA is a bioactive signaling phospholipid
acting on a wide range of biological processes including
cell growth, migration, and morphology [166]. LPA is
detected in several biological fluids and tissues including
the brain [167]. It is synthesized from different enzym-
atic activities involving notably phospholipase A1 and
A2, monoacylglycerol kinase, but the main enzyme lead-
ing to LPA synthesis is autotaxin [168]. Autotaxin is a
multifunctional phosphodiesterase that converts lyso-
phospholipids into LPA through its lysophospholipase D
activity. To date, LPA effects are mediated through five
G protein coupled receptors. However, additional recep-
tors have been identified for their potential responsive-
ness to LPA [168–170]. Using knock-out mice for the
five most known LPA receptors (LPA-R), it was shown
that LPA plays key roles on inflammation [171], angio-
genesis [172], reproduction [173–175], brain develop-
ment, and neurogenesis [176, 177]. Indeed, LPA exerts
pleomorphic effects on neural progenitor cells from cor-
tex, and notably calcium-mediated conductance [178].
In the nervous system, neural progenitor cells, neurons,
oligodendrocytes, Schwann cells, astrocytes, and micro-
glia have been documented for expressing different
subsets of LPA receptors [168]. It partially explains why
LPA exerts a wide variety of effects on these different
cell types. Thus, LPA can favor proliferation and differ-
entiation of neural progenitor cells as shown by treat-
ment on ex vivo embryonic brain slice cultures resulting
in an increase cell survival and differentiation [179].
Furthermore, LPA has been shown to promote prolifera-
tion and differentiation in neurospheres [180, 181]. LPA
also displays effect on cell morphology and neurite for-
mation in both neural progenitor cells and neurons
[168]. It exhibits both cell death and survival properties
on neurons possibly due to differences in LPA concentra-
tion or signaling through different receptors [182–184].
For instance, it induces apoptosis and necrosis in hippo-
campal neurons [182]. LPA also exerts various effects on
glial and microglial cells, by modulating intracellular
calcium levels in oligodendrocytes, astrocytes, and micro-
glia [168]. It notably favors astrocytes and microglia prolif-
eration in vitro [185, 186]. Overexpression of autotaxin in
microglia and by consequences, increased levels of LPA,
protects the cells from an oxidative stress by increasing
the level of catalase [187] and decreases the inflammatory
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response at least partially through an upregulation of IL-
10 [188]. Interestingly, following brain injury, in human
postmortem brains, LPA receptors 1–3 and autotaxin are
only weakly expressed while LPA-R2 is increased and
autotaxin transcripts are decreased. Such data also
reinforce the fact that LPA signaling is involved in neuro-
trauma [189]. During embryogenesis, LPA-R1 was de-
tected in neural progenitors reinforcing a potential role of
LPA/LPA-R1 signaling in neurogenesis [190]. In addition,
LPAR-1 knock-out reduces brain cell proliferation, differ-
entiation, and cell survival in the mouse dentate gyrus,
consequently strongly impairing neurogenesis [176].
Autotaxin is widely expressed in the brain of mouse not-
ably in neurogenic niches while LPA-R1 displays a lower
and more discrete expression (Allen Brain Atlas [http://
www.brain-map.org], [84]).
Blood brain barrier, adipokines, inflammation,
and oxidative stress
The effects and actions of adipokines on the CNS are
dependent on their capacity to interact with the cells of
the BBB and eventually to enter the CNS (Fig. 2). As
mentioned above about the TNFα, some adipokines
including leptin can cross the BBB [9]. Concerning
adiponectin, its capacity to cross the BBB is question-
able. In one study, the results based on the measurement
of radioactive labeled adiponectin and concentration in
the cerebrospinal fluid indicate that adiponectin does
not cross the BBB but will affect the cells of the BBB
and indirectly affect the CNS acting via AMPK pathway
[9, 138]. In another work using adiponectin KO mice
and recombinant adiponectin, it is shown that adiponec-
tin crosses the BBB [191]. As the conclusion, these two
publications proposed opposite results concerning the
possibility of adiponectin to cross the BBB, and more
conclusive results will be needed to clarify this point.
The BBB is a key player in the adipokine signaling
from the periphery to the CNS. Inflammation and oxida-
tive stress associated with pathologies impact neurode-
generation and neurogenesis but also affect the BBB.
In this review, we highlighted the striking correlations
between metabolic syndrome and the prevalence of
neurological disorders and dementia including AD. White
adipose tissue was not initially envisioned as a source of
inflammatory factors. However, it is now well accepted
that WAT is a key player in the development of a chronic
low-grade inflammation associated with adiposity and
consequently obesity [192, 193] with elevated production
of pro-inflammatory cytokines, such as TNFα, IL-6, and
IL-1 [194, 195]. In contrast, loss of WAT is associated
with a decrease in inflammation markers [196, 197]. Inter-
estingly, chronic and low-grade inflammation has been
proposed to negatively favor neurodegenerative diseases
through the disruption of the BBB. Indeed, the blood brain
barrier is a key interface linking systemic inflammation,
neuroinflammation, and neurodegeneration [198], inflam-
matory factors being a main cause of the BBB disruption
[199]. For instance, studies established positive correla-
tions between mid-life adiposity in women with disruption
of BBB integrity, showing that overweight/obesity could
favor the onset of vascular disorders increasing BBB per-
meability later in life [200]. In the same line of evidence,
rats fed with Western diet, known for promoting diabetes
and obesity, display a leakier BBB due to the decreased
expression of tight junctions [201]. Kanoski and colleagues
have also shown that a primary cerebral target following
BBB disruption is the hippocampus, well-known for its
involvement in cognitive processes [201]. This is of pecu-
liar interest given that AD patients display hippocampal
atrophy and disruption of fronto-hippocampal connec-
tions early in the course of the disease [202–204]. This is
further reinforced by the fact that AD in human and
rodent models is strongly linked to an increased perme-
ability of the BBB [205, 206]. Consequently, the chronic
low-grade inflammation that takes place in obese and dia-
betic people could negatively favor brain inflammation
and degeneration through BBB disruption.
Some interesting links exist between dietary factors
displaying anti-inflammatory properties, inflammation,
and disease outcomes. For instance, polyphenols such as
flavonoids and curcumin and spices such as cinnamon
have been suggested to decrease pro-inflammatory cyto-
kines, inflammation, and cardiovascular diseases and
type 2 diabetes which are known to be risk factors for
AD (for a recent review on this topic see ref [207]).
Conclusions
While the causal nature of all the processes leading to
neurodegeneration has not been definitively established, it
is widely accepted that neuroinflammation and oxidative
stress responses occur with clinical manifestation of the
disease. In this review, we described the impact of pro-
inflammatory adipokines (TNFα and leptin) on brain
homeostasis and functions. In addition, pro-inflammatory
adipokines play a major role in the production of reactive
oxygen species (ROS) [208, 209]. Due to its ability to
secrete adipokines that promote ROS production, WAT
has been regarded as an independent factor provoking
oxidative stress [210–212]. Exposure to obesity for a long
time in a host system downregulates and depletes the
activity of antioxidant enzymes such as superoxide dis-
mutase (SOD), catalase (CAT), and glutathione peroxidase
(GPx); these enzymes being found to be significantly
lowered compared with healthy persons which in turn
lead to the development of obesity-related health prob-
lems [213]. In addition to this, levels of vitamin A and
levels of serum antioxidants, such as vitamin E, vitamin C,
and β-carotene, as well as glutathione, are also decreased
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in obesity [214]. When compared to the normal or lean
individuals, obese individuals exhibit high levels of
biomarkers of oxidative damage and inflammation such as
C-reactive protein, LDL oxidation, and triglyceride levels
[215]. Thus, apart from inflammation, which is quite well-
known to be one of the critical factors that damages the
brain, ROS production which exceeds the antioxidant
defenses in the host system is another factor that can also
result in brain damages [216]. Cytokines produced by the
monocytes and macrophages in WAT are the potent stim-
ulators for the production of reactive oxygen (ROS) and
nitrogen species (RNS) which generates oxidative stress.
Adipose tissue also has the secretory capacity of angioten-
sin II, which stimulates nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase activity. NADPH oxidase
comprises the major route for ROS production in adipo-
cytes [217]). Thus, obesity results in an increased oxidative
stress status that can lead to neural dysfunction and death
Fig. 2 Adipokines and LPA interactions with the blood brain barrier and the central nervous system. The BBB is composed of endothelial cells
(displaying tight junctions), pericytes and astrocytes. a In physiological conditions, some adipokines such as leptin and TNFα can cross the BBB
through different mechanisms and act on the central nervous system. b Adipokines can also activate endothelial cell receptors resulting in the
modulation of the expression of tight junctions and in the modulation of the BBB permeability. In adiponectin case, one study reports its crossing
through the BBB [191], while another indicates that it does not cross the BBB [138]. Both possibilities are shown. In inflammatory conditions, the
BBB is leaking and could allow an increase passage of adipokines and LPA into the CNS, leading to an increase of oxidative stress and
neurodegeneration (c)
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[218, 219]. It has been reported that obesity may induce
systemic oxidative stress and, in turn, oxidative stress is
associated with an irregular production of adipokines,
which contributes to the development of the metabolic
syndrome [220]. In parallel, oxidative stress is implicated
in numerous neurological diseases and/or disorders such
as AD, PD, amyotrophic lateral sclerosis (ALS), multiple
sclerosis (MS), cerebral ischemia/reperfusion injury, and
TBI, promoting neurodegeneration [221]. An increasing
number of studies using in vitro models and knock-out
animals demonstrate that oxidative stress disrupts the
BBB permeability [221–223].
Taken together, these data suggest that in pathological
conditions, adipokines released by WAT promote inflam-
mation and ROS production that may disrupt the BBB
permeability and could directly or indirectly act on diff-
erent brain structures, the hippocampus being one of the
most sensitive areas. It could explain why metabolic
syndrome is associated with hippocampus atrophy and an
increase risk to develop dementia such as AD. One main
issue in people suffering from metabolic syndrome should
be to struggle against inflammation and reduce oxidative
stress in order to decrease their potential effects on brain
neurodegeneration and their adverse effects.
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